- Home
- CRDL vs SILC Comparison
CRDL vs SILC Comparison
Compare CRDL & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- SILC
- Stock Information
- Founded
- CRDL 2017
- SILC 1987
- Country
- CRDL Canada
- SILC Israel
- Employees
- CRDL N/A
- SILC N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- SILC Computer Manufacturing
- Sector
- CRDL Health Care
- SILC Technology
- Exchange
- CRDL Nasdaq
- SILC Nasdaq
- Market Cap
- CRDL 102.0M
- SILC 104.7M
- IPO Year
- CRDL N/A
- SILC 1994
- Fundamental
- Price
- CRDL $1.20
- SILC $16.60
- Analyst Decision
- CRDL Strong Buy
- SILC Hold
- Analyst Count
- CRDL 3
- SILC 2
- Target Price
- CRDL $9.00
- SILC N/A
- AVG Volume (30 Days)
- CRDL 274.8K
- SILC 16.6K
- Earning Date
- CRDL 03-31-2025
- SILC 01-30-2025
- Dividend Yield
- CRDL N/A
- SILC N/A
- EPS Growth
- CRDL N/A
- SILC N/A
- EPS
- CRDL N/A
- SILC N/A
- Revenue
- CRDL N/A
- SILC $58,114,000.00
- Revenue This Year
- CRDL N/A
- SILC $6.22
- Revenue Next Year
- CRDL N/A
- SILC $19.10
- P/E Ratio
- CRDL N/A
- SILC N/A
- Revenue Growth
- CRDL N/A
- SILC N/A
- 52 Week Low
- CRDL $1.15
- SILC $11.35
- 52 Week High
- CRDL $3.12
- SILC $18.24
- Technical
- Relative Strength Index (RSI)
- CRDL 41.60
- SILC 47.87
- Support Level
- CRDL $1.15
- SILC $16.35
- Resistance Level
- CRDL $1.51
- SILC $17.46
- Average True Range (ATR)
- CRDL 0.10
- SILC 0.63
- MACD
- CRDL -0.01
- SILC -0.09
- Stochastic Oscillator
- CRDL 13.65
- SILC 17.11
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.